RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The RPSSunny, when spinco was being created I was as happy as could be thinking that if the ASSURE trial succeeded it would lend huge credibility to what would become Zenith and now ZCC and ZEN. Well, ASSURE was deemed a failure in terms of not reaching the PAV regression target. Hence an enormous judgement by the market killed the credibility of RVX and I believe raised big doubts about the entire RVX and Zenith epigenetic platforms.
I never sold my shares during that time and have continued to add.
We've all seen the incredible results and learning coming out of the post hocs.
Here is something I posted a while back when I started to realize the significance of scaffolds and I apologize to BDAZ if I got it is wrong and stand to be corrected.
- "I am reposting a question that I had put to BDAZ regarding scaffolds because Don refers to CEPT inhibitors being based on (the old) benzodiazepine scaffold. From the way I understand it CEPT inhibitors have been successful in significantly increasing HDL but there is no indication that this reduces reverse cholesterol transport. We already know that rvx-208 increases apoa-l (HDL) and the post hocs showed strong reductions in MACE (55% RRR).BDAZ describes the scaffolds as the backbone on which compounds are based and indicated that the patents don’t just apply to individual compounds but to the scaffolds, therefore cover the scaffolds and compounds related to those scaffolds. So to me this adds tremendous value to both RVX and Zenith as companies."
So this raises questions about the potential tremendous value of the RVX and Zentih scaffolds and how difficult they are to copy (i.e. if a competitor's scaffold does not work even though they increase HDL?)
Without going through the litany of discoveries that have been made about apabetalone, all of which are positive, I am biased toward the continued success of both companies.
Don's current restructuring of the Zenith royalties related to RVX and not just Apoa-l compounds seems to open up business opporturtunities and flexibility to "deal" options. Of course, in the near term the licensing deal seems to be the most likely option at RVX. If it happens then who the new partner is will tell us loads about where all of this is headed.
It seems to that the obvious drivers of equity are;
- The BETonMACE futility analysis for apebetalone.
- The mCRPC trial for zen3694.
Success on either I believe will have a significant impact on the value of both companies. However, both are probably Q4 2017 events so we have a year to sit back.
Don has spoken about other revenue generating options over the years;
- The large properitary blood bank which can be used by other biotechs and BP to test their compounds.
- The possibility to license out any one of the 2500 epigenetic Zenith compounds and / or the 1400 RVX compounds to other biotechs for accelerated development.
So if RVX and Zenith control the scaffolds used to produce the compounds then I would assume they would use them to produce specific compounds at a price for interested clients i.e. selling product.
And now...back to your point;
- Don promised a Zenith IPO would happen in Q4 2015.
- In an update I think in Feb 2016 Don talked about providing a reverse take over of a distressed company that has a NASDAQ and/or TSX listing in order to provide liquidity to Zenith shares.
- Then there was the restructuring to Zenith Capital and ZEN epigenetics.
I don't see any liquidity happening until there is a compound to do an IPO on and Zen Capital will remain private and protected.
In my trading account my Zenith shares are listed with a value of $0.00. That happened a few months ago.
I'd love to hear other POVs on this. I just realized I rambled on here thinking out loud again.
GLTA
Toinv